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Abstract
Background: In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall 
survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients 
with metastatic colorectal cancer refractory or intolerant to standard therapies. The present 
analysis investigated the efficacy and safety of trifluridine/tipiracil in RECOURSE subgroups.
Methods: Primary and key secondary end-points were evaluated using a Cox proportional 
hazards model in prespecified subgroups, including geographical subregion (United States of 
America [USA], European Union [EU], Japan), age (<65 years, ≥65 years) and v-Ki-ras2 Kirsten 
rat sarcoma 2 viral oncogene homologue (KRAS) status (wild type, mutant). Safety and 
tolerability were reported with descriptive statistics.
Results: Eight-hundred patients were enrolled: USA, n = 99; EU, n = 403; Japan, n = 266. 
Patients aged ≥65 years and those with mutant KRAS tumours comprised 44% and 51% of all 
patients in the subregions, respectively. Final OS analysis (including 89% of events, compared 
with 72% in the initial analysis) confirmed the survival benefit associated with trifluridine/
tipiracil, with a hazard ratio (HR) of 0.69 (95% confidence interval [CI] 0.59–0.81; P = 0.0001). 
Median OS in the three regions was 6.5–7.8 months in the trifluridine/tipiracil arm and 4.3–6.7 
months in the placebo arm (USA: HR 0.56; 95% CI 0.34–0.94; P = 0.0277; EU: HR 0.62; 95% CI 
0.48–0.80; P = 0.0002; Japan: HR 0.75; 95% CI 0.57–1.00; P = 0.0470). Median PFS was 2.0–2.8 
months for trifluridine/tipiracil and 1.7–1.8 months for placebo; HRs favoured trifluridine/tipiracil 
in all regions. Similar clinical benefits of trifluridine/tipiracil were observed in elderly patients and 
in those with mutant KRAS tumours. There were no marked differences among subregions in 
terms of safety and tolerability.
Conclusions: Trifluridine/tipiracil was effective in all subgroups, regardless of age, 
geographical origin or KRAS status.
This trial is registered with ClinicalTrials.gov: NCT01607957.
Keywords
Fluoropyrimidine; Metastatic colorectal cancer; Randomised controlled trial; TAS-102; Tipiracil; 
Trifluridine
1. Introduction
Trifluridine/tipiracil (TAS-102, Lonsurf®; Taiho Oncology Inc., Princeton, NJ, USA) is an 
orally administered chemotherapy consisting of the antineoplastic thymidine-based 
nucleoside analogue trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, at a 
molar ratio of 1:0.5 (weight ratio, 1:0.471). The primary cytotoxic mechanism of trifluridine 
is through incorporation into DNA, leading to DNA dysfunction and damage [1–3]. The 
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addition of tipiracil improves the bioavailability of trifluridine by inhibiting its catabolism 
by thymidine phosphorylase [4].
Trifluridine/tipiracil has shown promise in a number of clinical trials, particularly in 
metastatic colorectal cancer [5–10]. In the phase III RECOURSE trial (NCT01607957), 
which was conducted in patients with metastatic colorectal cancer refractory to standard 
therapies, including fluoropyrimidines, irinotecan and oxaliplatin, treatment with 
trifluridine/tipiracil resulted in a significant improvement in median overall survival (OS) 
compared with placebo (7.1 versus 5.3 months; hazard ratio [HR] 0.68; P < 0.0001) and in 
median progression-free survival (PFS) (2.0 versus 1.7 months; HR 0.48; P < 0.0001) [5]. 
Trifluridine/tipiracil was well tolerated, with few serious adverse events (AEs) reported; 
neutropenia was the most frequently observed AE. Many patients in this trial [5], as well as 
all patients in the prior phase II trial [10], were Japanese. Therefore, it is of interest to 
compare the efficacy and safety of trifluridine/ tipiracil in Western populations with those 
reported from Japan. The current analyses were performed to further evaluate trifluridine/
tipiracil compared with placebo among different patient groups, including geographical 
subregions, older patients aged ≥65 and ≥70 years, and v-Ki-ras2 Kirsten rat sarcoma 2 viral 
oncogene homologue (KRAS) status.
2. Patients and methods
2.1. Study design
The RECOURSE trial design has been previously described in detail (Supplementary Fig. 1) 
[5]. Briefly, RECOURSE was a global, phase III, multicentre, randomised, double-blind, 
placebo-controlled trial comparing trifluridine/tipiracil plus best supportive care on the one 
hand with placebo plus best supportive care on the other. Patients were stratified according 
to (1) KRAS status (wild type, mutant), (2) time since diagnosis of first metastasis (<18 
months, ≥18 months) and (3) geographical region (Japan and Western [United States of 
America (USA), European Union (EU) including United Kingdom, and Australia]), and 
randomly assigned in a 2:1 ratio to receive trifluridine/tipiracil or placebo. Here, we assess 
results based on geographical subregions (Japan, USA and EU) and outcomes related to age 
and KRAS status. Patients were randomised at 21 different sites in the USA, 20 in Japan and 
55 across the EU. Australia was omitted from this analysis because of the small number of 
enrolled patients (n = 32).
2.2. Patients
Patients with biopsy-proven/documented adenocarcinoma of the colon or rectum who had 
received two or more regimens of standard chemotherapies for metastatic disease were 
eligible for randomisation. For more details, please see the supplementary methods.
2.3. End-points
The primary end-point was OS, defined as the time from randomisation to death from any 
cause. Secondary end-points included PFS (time from randomisation to first radiographical 
confirmation of disease progression or death from any cause), overall response rate 
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(proportion of patients with complete or partial response) and safety. Measurements are 
described in the supplementary methods.
2.4. Statistical analysis
The study protocol included a prespecified analysis of outcomes and safety according to 
geographical subregion, KRAS status and potential prognostic/predictive factors, including 
age <65 versus ≥65 years and <70 versus ≥70 years. OS and PFS were analysed in the 
intention-to-treat population in each geographical subregion with the use of a two-sided, 
stratified, logrank test, with the HR and two-sided 95% confidence intervals (CIs) based on a 
stratified Cox proportional hazards model and the associated Kaplan–Meier survival 
estimates. Median follow-up time for survival was calculated by means of the reverse 
Kaplan–Meier method. AEs and laboratory abnormalities were summarised for all patients 
who received at least one dose of study drug. The number and percentage of patients 
hospitalised, reason for hospitalisation and total duration of hospitalisation were summarised 
descriptively by treatment group for each region. Ad hoc analyses of outcomes across 
subregions according to age ≥65 years, age ≥70 years and KRAS status were also conducted 
using the same methodology.
The original results of RECOURSE were based on a cut-off date of 24th January 2014 [5]. 
A further analysis of OS outcomes was performed based on final survival data as of 8th 
October 2014 and is presented here. Additionally, a multivariate model of potential 
prognostic factors was developed to create a prognostic index for OS, and included KRAS 
status, time since diagnosis of first metastasis, geographical subregion, v-raf murine sarcoma 
viral oncogene homologue B1 (BRAF) status, age, race, gender, primary tumour site, 
Eastern Cooperative Oncology Group performance status (ECOG PS), number of prior 
regimens and number of metastatic sites [11].
3. Results
3.1. Baseline characteristics
Of the 800 patients (excluding the 32 from Australia) enrolled in the RECOURSE trial, 99, 
403 and 266 were enrolled in the USA, EU and Japan, respectively. Baseline characteristics 
for patients randomised within these subregions are shown in Table 1. Elderly patients aged 
≥65 and ≥70 years represented 44% and 23% of all patients enrolled within the three 
geographical subregions, respectively; patients with mutant KRAS tumours accounted for 
51% of patients. There were some differences in the racial profile of patients from these 
subregions, with US and EU patients being predominantly Caucasian, and Japanese patients 
being Asian. More than 60% of patients in the EU and Japan were male individuals 
compared with approximately 50% in the USA. In Japan, the primary tumour site was 
evenly divided between colon and rectum, while in the EU, and particularly in the USA, the 
majority of primary tumour sites were in the colon. Japanese patients appeared to have less 
symptomatic disease, with 71% having an ECOG PS of 0 compared with 41% in the USA 
and 51% in the EU. In addition, 75.2% of Japanese patients had a normal baseline estimated 
glomerular filtration rate compared with 48% in the USA and 56% in the EU.
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Median OS in the three geographical subregions ranged from 6.5 months in the USA to 7.8 
in Japan in the trifluridine/tipiracil arm and from 4.3 months in the USA to 6.7 in Japan in 
the placebo arm (Fig. 1A and B). Although the longest median OS was observed in Japan, 
the improvement was greater in the USA and the EU with HRs of 0.56 (95% CI 0.34–0.94; 
P = 0.0277) and 0.62 (95% CI 0.48–0.80; P = 0.0002), respectively, compared with 0.75 
(95% CI 0.57–1.00; P = 0.047) in Japan. Similar trends were reported for PFS, with HRs 
favouring trifluridine/tipiracil in all three geographical subregions (Fig. 1C and D).
At the time of the data cut-off for the final survival analysis (8th October 2014), 89% of the 
800 patients randomised had died, accounting for 138 additional deaths to the 574 (72%) 
previously included in the original analysis [6]. Median OS in this updated analysis was 7.2 
months for trifluridine/tipiracil versus 5.2 months for placebo, with an HR of 0.69 (95% CI 
0.59–0.81; P < 0.0001) (Fig. 2). Although the median OS benefit was slightly longer than in 
the original analysis (2.0 versus 1.8 months), the outcome pattern remains consistent with 
the original analysis [5]. The final prognostic risk model identified primary tumour site 
(colon versus rectum), ECOG PS and number of metastatic sites as prognostic risk factors, 
in addition to the three stratification factors that were included by default. When patients 
were divided into quartiles by OS according to these prognostic risk factors, the median OS 
ranged from 4.6 to 10.5 months in the highest- and lowest-risk quartiles, respectively, in the 
trifluridine/tipiracil arm, and from 3.5 to 7.1 months, respectively, in the placebo arm 
(Supplementary Table 1). The HR favoured trifluridine/tipiracil over placebo in all quartiles, 
ranging from 0.67 in the lowest-risk quartile to 0.56 in the highest-risk quartile. Survival 
rates 1 year after randomisation in this final analysis were 27.1% (95% CI 23.3–30.9) and 
16.6% (95% CI 12.4–21.4) in the trifluridine/tipiracil and placebo arms, respectively.
Table 2 depicts HRs for OS and PFS for patients aged ≥65 years overall and in the USA, the 
EU and Japan. Median OS for patients aged ≥65 years was 7.0 months in the trifluridine/
tipiracil arm, significantly longer than the 4.6 months reported in the placebo arm (HR 0.62; 
95% CI 0.48–0.80; P = 0.0002). Similar to the population as a whole, the outcome results 
favoured trifluridine/tipiracil for OS and PFS in each region. Importantly, results for these 
elderly patients were similar to those for the overall population in each subregion, consistent 
with the prognostic model that had rejected age as a prognostic factor. Similar results were 
noted in an analysis of all patients aged ≥70 years across all three regions; median OS in this 
age group was 7.0 months in the trifluridine/tipiracil arm compared with 4.7 in the placebo 
arm (HR 0.65; 95% CI 0.45–0.94; P = 0.0231). HRs for OS and PFS by KRAS are shown in 
Table 3. OS was longer for patients with wild-type KRAS than for those with mutant KRAS 
in both the trifluridine/tipiracil and placebo arms overall and among all regions; HRs for OS 
favoured trifluridine/ tipiracil over placebo regardless of KRAS status, although this benefit 
for patients with mutant KRAS did not reach statistical significance (P = 0.0712). PFS was 
significantly longer for wild-type and mutant KRAS (both P < 0.0001) in the population as a 
whole; HRs again favoured trifluridine/tipiracil but did not reach statistical significance in 
all subregions.
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3.3. Safety and hospitalisation
There were no significant differences among the US, EU and Japanese subgroups and the 
overall population with respect to the incidence of AEs, grade ≥3 AEs, serious AEs or 
hospitalisations (Table 4). Almost all patients experienced an AE, with 98.5%, 96.9% and 
99.4% of trifluridine/tipiracil patients and 91.6%, 100% and 92.0% of placebo patients 
having at least one AE of any grade in EU, US and Japanese subgroups, respectively. The 
incidence of AEs and haematological laboratory abnormalities of grade ≥3, which were 
reported in ≥5% of patients in any subregion, are shown in Table 4. The most commonly 
reported AEs were neutropenia in the USA and EU and anaemia in Japan, but there were no 
consistent differences between Asian and Western populations with respect to grade 3 or 4 
clinical AEs or haematological abnormalities.
Table 4 also provides details of hospitalisation for any reason in the RECOURSE trial by 
subregion. Although there were no important differences in hospitalisation rates in 
association with trifluridine/tipiracil treatment, there was a slightly higher number of 
hospitalisations within the placebo cohort in Japan compared with the USA and EU. The 
hospitalisation rate was higher in the placebo arm than in the trifluridine/tipiracil arm in all 
regions. Duration of hospital stay was also longer in each region for the placebo arm than for 
the trifluridine/tipiracil arm. Median length of stay was longer in Japan than in the USA and 
the EU for both trifluridine/tipiracil and placebo arms. Serious AEs were the most common 
reason for hospitalisation.
4. Discussion
The efficacy and safety of trifluridine/tipiracil were similar across all three geographical 
subregions (USA, EU and Japan) and were consistent with the overall RECOURSE 
population. Improved OS and PFS were observed overall and within each geographical 
subgroup randomised to trifluridine/tipiracil versus placebo, with an acceptable safety 
profile. Notably, OS in both the trifluridine/tipiracil and placebo groups in Japan was 
somewhat longer than that observed in the same treatment groups in the other regions (7.8 
versus 6.5–6.8 months for trifluridine/tipiracil; 6.8 versus 4.3–4.9 months for placebo). This 
result was consistent with what had been observed in an earlier phase II study conducted in a 
similar Japanese population in which the observed median OS values were 9.0 and 6.6 
months in the trifluridine/tipiracil and placebo groups, respectively (HR 0.56; 95% CI 0.39–
0.81; P = 0.011) [10].
Differences in baseline characteristics were observed between the Western and Japanese 
populations in the RECOURSE trial, which may help to explain regional differences in OS. 
As expected, the Japanese population was entirely Asian, whereas the US and EU 
populations were predominantly Caucasian. The similarity in efficacy among these regions 
encourages the generalised applicability of the results. Patients enrolled in Japan were more 
likely to have an ECOG PS of 0 and have a normal estimated glomerular filtration rate than 
patients enrolled in the USA or the EU, perhaps suggesting that Japanese patients had less 
advanced disease at study enrolment than their Western counterparts. This may explain the 
better prognosis at baseline and longer OS and PFS in both the trifluridine/tipiracil and 
placebo arms in Japan.
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This updated survival analysis is based on reports of clinical events in 89% of randomised 
patients compared with the initial analysis that was based on reports of clinical events in 
72% of such individuals [5]. The reported HR of 0.69 (95% CI 0.59–0.81; P < 0.0001) from 
this analysis, compared with 0.68 (95% CI 0.58–0.81; P < 0.001) in the original analysis, 
reveals that the OS benefit with trifluridine/tipiracil was maintained, with median OS 
increasing from 1.8 to 2.0 months. This survival benefit appears to be present in all patients 
regardless of their prognostic status at the time of trial entry. The prognostic risk model 
developed identified primary tumour site, ECOG PS and number of metastatic sites as 
meaningful prognostic risk factors, in addition to the default stratification factors, which 
included KRAS status, time since diagnosis of first metastasis and geographical subregion. 
A number of attempts have been made in recent years to develop prognostic risk models for 
metastatic colorectal cancer [12–15]. Although there are differences in methodology and 
patient populations among these analyses, ECOG PS, KRAS status and number of 
metastatic sites are factors common to many models. KRAS status was included in the 
model developed here by default as it was a stratification factor; however, our results 
demonstrated that patients with wild-type KRAS generally had a better overall outcome than 
those with mutant KRAS tumours. The importance of KRAS as a prognostic factor outside 
the context of targeted treatment is controversial [12], although some studies have 
demonstrated poorer outcomes in patients with KRAS mutations at codon 12 and in those 
with metastatic disease [16,17]. The model developed here is somewhat different from other 
models as it did not include treatment, allowing for the evaluation of trifluridine/tipiracil in 
different prognostic groups. Results showed all patients benefited equally from trifluridine/
tipiracil, regardless of risk factor (including KRAS status), with no effect from the 
prognostic index. HRs for OS and PFS favoured trifluridine/tipiracil over placebo 
irrespective of KRAS status. However, these differences did not reach statistical significance 
in every subgroup across geographical regions, indicating that the decision to treat with 
trifluridine/tipiracil should not be influenced by prognostic factors if patients have a suitable 
physical condition with adequate organ function consistent with the entry criteria for this 
study. Results for patients aged ≥65 and ≥70 years were similar to those for the general 
population overall and in each subregion, indicating that trifluridine/tipiracil is a tolerable 
treatment option in older patients.
Trifluridine/tipiracil was generally well tolerated in the RECOURSE trial, with few 
differences among subregions. Any differences in the incidence of individual AEs between 
the Western and Japanese populations may be due to variations in the interpretation of terms 
used to define certain events, rather than any true differences in tolerability. For instance, the 
rate of neutropenia in Japan was reported as being substantially lower than elsewhere, 
although the rates of reduced neutrophil counts and febrile neutropenia were similar. 
Hospitalisation rates and reasons for hospitalisation were similar across subregions, and 
were consistently lower for trifluridine/tipiracil than for placebo. However, the median 
length of stay following hospitalisation for both treatment groups was longer in Japan, 
perhaps due to the lower cost of hospitalisation in this region.
Although the analysis of efficacy in geographical subregions was preplanned, the 
comparisons in this study are limited by the low number of patients in some subregions. 
Notably, the number of patients enrolled in the US subregion (n = 99) was substantially 
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lower than that in the EU or Japanese subregions (n = 403 and n = 266, respectively). 
Therefore, despite being stratified by geographical area (Japan versus USA, EU and 
Australia combined), sample sizes may have been too small to detect differences between 
trifluridine/tipiracil and placebo in or between subregions. This issue may be compounded 
when examining ad hoc analyses of subpopulations, such as elderly patients, within these 
subregions.
5. Conclusion
OS and PFS benefits were observed in patients randomised to trifluridine/tipiracil compared 
with placebo in the USA, the EU and Japan, and were consistent with the results from the 
overall RECOURSE trial, with an acceptable safety profile. These benefits were observed in 
all defined prognostic subgroups, including elderly subpopulations. Overall, the results of 
this analysis provide confidence that trifluridine/tipiracil is safe and effective, regardless of 
age, KRAS status, racial/ethnic differences or other regional differences in geographically 
disparate patient populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Kaplan–Meier curves and forest plots for overall survival (OS) and progression-free 
survival (PFS).
(A) Kaplan–Meier curve for OS by geographical subregion; (B) forest plot for OS by 
geographical subregion; (C) Kaplan–Meier curve for PFS by geographical subregion; (D) 
forest plot for PFS by geographical subregion. Abbreviations: CI, confidence interval; FTD/
TPI, trifluridine/tipiracil; HR, hazard ratio; ITT, intention-to-treat.
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Fig. 2. Overall survival as of 8th October 2014 (intention-to-treat population).
Abbreviations: CI, confidence interval; FTD/TPI, trifluridine/tipiracil; HR, hazard ratio; OS, 
overall survival.
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